Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
United Therapeutics Corporation(UTHR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for UTHR
11/13/2026: UTHR (4-star) is a STRONG-BUY. BUY for 17 days. Simulated Profits (1.09%). Updated daily EoD!
United Therapeutics Corporation is a specialized biotechnology company focused on treating pulmonary arterial hypertension and pioneering organ manufacturing technologies. Its primary strengths lie in its successful delivery of innovative treprostinil-based therapies and a robust, founder-led business model. The investment story centers on the commercial success of products like Tyvaso and the long-term potential of its xenotransplantation pipeline. Key risks include heavy reliance on a narrow product portfolio, intensifying generic competition, and regulatory uncertainties. This stock typically suits growth-oriented investors with a high risk tolerance, and observers should monitor upcoming clinical trial results and patent litigation closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company's focus on innovative therapies and organ manufacturing provides a strong narrative for long-term capital appreciation. |
| Momentum investor | Mixed fit | Momentum is often linked to clinical trial news and regulatory updates, requiring a positive trend signal. |
| Value investor | Mixed fit | The valuation reflects high growth expectations, which may not align with traditional value metrics. |
| Dividend investor | Weak fit | The company does not pay a dividend as it prioritizes reinvestment into its R&D pipeline. |
| Low-risk investor | Weak fit | As a biotechnology firm subject to clinical and regulatory risks, the stock exhibits higher volatility than stable blue-chip companies. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | Biotech stocks are highly sensitive to clinical data results and regulatory decisions. |
| Valuation risk | Medium | Growth expectations are high, making the stock sensitive to earnings misses. |
| Competition risk (PAH market) | High | Generic entry and large pharma competitors put pressure on pricing and market share. |
| Business quality | Strong | The company has established a stable, profitable core business with a clear mission. |
| Dividend income | Low / none | Investors should not expect income from this equity investment. |
| Execution risk | Medium | Successfully bringing complex organ manufacturing to market involves significant operational challenges. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 25.18B USD | Price to earnings Ratio 22.32 | 1Y Target Price 687.14 |
Price to earnings Ratio 22.32 | 1Y Target Price 687.14 | ||
Volume (30-day avg) 636.1K shares | Beta 0.48 | 52 Weeks Range 455.63 - 614.23 | Updated Date 11/13/2026 |
52 Weeks Range 455.63 - 614.23 | Updated Date 11/13/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 26.49 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Drug Manufacturers - Specialty & Generic
- BUY participation
- 66.7%
- Active BUY / eligible
- 8 / 12
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Flat / Range-Bound
The stock price has been trading within a narrow range with minimal directional movement.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 93.75% | Avg. Invested days 49 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 11/13/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Commercialized PAH Therapies | Tyvaso, Remodulin, and Orenitram sales. | The company generates the vast majority of its revenue from specialty drugs used to treat pulmonary arterial hypertension. |
| Organ Transplantation Technology | Research and development in ex-vivo lung perfusion and xenotransplantation. | This is a long-term R&D investment area designed to solve organ shortages and currently does not contribute significant revenue. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-04 | When Before Market | Estimate 5.85 | Actual 5.71 |
Profitability
Profit Margin 38.61% | Operating Margin (TTM) 39.38% |
Management Effectiveness
Return on Assets (TTM) 10.91% | Return on Equity (TTM) 19.13% |
Valuation
Trailing PE 22.32 | Forward PE 18.8 | Enterprise Value 22.15B | Price to Sales(TTM) 7.9 |
Enterprise Value 22.15B | Price to Sales(TTM) 7.9 | ||
Enterprise Value to Revenue 6.95 | Enterprise Value to EBITDA 13.71 | Shares Outstanding 42.59M | Shares Floating 38.91M |
Shares Outstanding 42.59M | Shares Floating 38.91M | ||
Percent Insiders 2.02 | Percent Institutions 101.71 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.